Amgen, Novartis Launch Neuroscience Drug Collaboration

Amgen will expand into Alzheimer’s disease treatments, and Novartis will add to its presence in neuroscience drugs, by co-developing and co-commercializing new beta-site APP-cleaving enzyme-1 (BACE) inhibitors designed to fight the memory-robbing illness. The value of the collaboration was not disclosed. But in announcing a neuroscience collaboration yesterday that will also focus on developing treatments for migraine, the companies did say that Novartis’ Phase I/IIa oral BACE inhibitor CNP520 will be the lead molecule to be developed and commercialized. CNP520 is an oral drug designed to prevent the production of different forms of amyloid, and thus has the potential to prevent, slow, or delay the symptoms associated with Alzheimer’s, according to Novartis. CNP520 is planned to be included in a prevention study in people with a genetic risk of developing the…


Link to Full Article: Amgen, Novartis Launch Neuroscience Drug Collaboration